Compliance Architects® continues to innovate and exceed client expectations through an expanded portfolio of product and service offerings. These include:

An innovative approach to strategic quality planning and prioritized remediation activities enabled by the firm’s CRPN Quality Roadmap® offering. This service is comprised of a defined, structured methodology, proprietary risk and complexity algorithms, and cloud-based software tool that together facilitates intelligent, semi-quantitative, risk-based planning for FDA-regulated companies.

Enhancements and upgrades to the breakthrough Writing for Compliance® workshop training program; FDA-regulated industry’s first and only training program devoted to improving FDA and regulatory inspection outcomes through improving writing.

“Compliance Architects® has an outstanding track record of success guiding its customers through the ever-changing regulatory environment. I’m excited to be part of a company that is deploying and developing the industry’s top consultants and services,” said Grizzel.

Grizzel is a highly-regarded industry veteran with more than 20 years of experience as a successful team leader. Before joining Compliance Architects®, Grizzel served as Director of Business Development at FDAnews. Prior to that, he served as Conference Director and was responsible for developing the FDAnews Inspections Summit – now in its 14th year.

“Jeff’s extensive sales and branding experience will be invaluable for Compliance Architects® as we expand upon our demonstrated client successes,” said Jack Garvey, Compliance Architects’ CEO. “We’re excited for Jeff to join the team as his strong sales and business expertise – and deep industry contacts – allow us to continue bringing innovative solutions to our clients.”

About Compliance Architects LLC

Compliance Architects® delivers compliance and quality consulting, outsourcing, staff augmentation, and technology-related services to FDA-regulated companies. Compliance Architects® has the experience, expertise and delivery capability that will result in significantly improved FDA compliance outcomes for any size organization.